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A direct HPLC method was developed for the enantioseparation of
pantoprazole using macrocyclic glycopeptide‐based chiral stationary phases,
along with various methods to determine the elution order without isolation
of the individual enantiomers. In the preliminary screening, four macrocyclic
glycopeptide‐based chiral stationary phases containing vancomycin
(Chirobiotic V), ristocetin A (Chirobiotic R), teicoplanin (Chirobiotic T), and
teicoplanin‐aglycone (Chirobiotic TAG) were screened in polar organic and
reversed‐phase mode. Best results were achieved by using Chirobiotic TAG col-
umn and a methanol‐water mixture as mobile phase. Further method optimi-
zation was performed using a face‐centered central composite design to
achieve the highest chiral resolution. Optimized parameters, offering baseline
separation (resolution = 1.91 ± 0.03) were as follows: Chirobiotic TAG station-
ary phase, thermostated at 10°C, mobile phase consisting of methanol/20mM
ammonium acetate 60:40 v/v, and 0.6 mL/min flow rate. Enantiomer elution
order was determined using HPLC hyphenated with circular dichroism (CD)
spectroscopy detection. The online CD signals of the separated pantoprazole
enantiomers at selected wavelengths were compared with the structurally anal-
ogous esomeprazole enantiomer. For further verification, the inline rapid,
multiscan CD signals were compared with the quantum chemically calculated
CD spectra. Furthermore, docking calculations were used to investigate the
enantiorecognition at molecular level. The molecular docking shows that the
R‐enantiomer binds stronger to the chiral selector than its antipode, which is
in accordance with the determined elution order on the column—S‐ followed
by the R‐isomer. Thus, combined methods, HPLC‐CD and theoretical calcula-
tions, are highly efficient in predicting the elution order of enantiomers.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Chiral synthesis, isolation of chiral compounds from natu-
ral sources, or simply HPLC enantioseparation are all com-
mon situations when the absolute configuration of the
investigated compounds may be questionable, and the iso-
lation is not possible for various reasons, such as the small
sample quantity or due to the fast decomposition of the
analyte. In this case, the hyphenation of circular dichroism
(CD) measurements with HPLC, supported by molecular
modeling can help to determine the absolute configuration
and the enantiomer elution order in chiral separations.
The aim of this workwas to develop amethod, which could
further be applied for the determination of absolute config-
uration of enantiomers in chiral separations without any
time‐ and labor‐intensive isolation. As a chiral model drug
of choice, pantoprazole was selected.
Pantoprazole, (5‐(difluoromethoxy)‐2‐[(3,4‐dimethoxy‐
2‐pyridyl) methylsulfinyl]‐1H‐benzimidazole), is a proton
pump inhibitor (PPI), frequently prescribed in gastric
hyperacidity‐related disorders (Figure 1). The molecule
has a chiral sulfoxide moiety, and it is used as a racemate
in therapy. However, it has been proved that its S‐
enantiomer has some therapeutic advantages over the
racemate, because of its stereoselective pharmacokinet-
ics.1,2 Moreover, one of the best‐known examples of chi-
ral switch is the structurally similar PPI, esomeprazole,
the S‐enantiomer of omeprazole (Figure 1).
Several chromatographic and electrophoretic tech-
niques, such as high‐performance liquid chromatography
(HPLC), capillary electrophoresis (CE), capillary
electrochromatography (CEC), thin layer chromatogra-
phy (TLC), supercritical fluid chromatography (SFC),
and gas chromatography (GC
) are frequently used for enantioseparation of phar-
maceutical substances. Among these techniques,
direct HPLC enantioseparations using chiralpantoprazole (left) and
hiral centerstationary phases (CSPs) is the golden standard in
this field.3
Macrocyclic antibiotics have been introduced as chiral
selectors for HPLC in 1994 by Armstrong et al.4 Since
then, it became clear that the macrocyclic glycopeptides,
such as teicoplanin, vancomycin, ristocetin A, and its ana-
logues, are among the most useful chiral selectors for the
enantioseparation of many biologically active compounds.
The variety and combination of their chiral interaction
capabilities, including electrostatic, hydrophobic, H‐
bonding, steric repulsion, dipole stacking, and π‐π‐
interactions, are the factors that make these chiral selec-
tors useful in chiral separations. Another advantage of
these CSPs includes their great versatility, which makes
them suitable in several combinations of mobile phases,
such as normal‐phase, reversed‐phase, and polar organic
mobile phase modes.5
Several HPLC chiral separation methods have been
published for the chiral discrimination of pantoprazole
enantiomers. The most frequently used CSPs for this pur-
pose are polysaccharide‐type CSPs such as Chiralcel OJ‐
R, Chiralpak IA, Chiralpak ID‐3, and Chiralpak IE‐3.6-9
However, studies using other CSP classes such as
protein‐based10 or ligand‐exchange11,12 have also been
published in the past two decades.
A validated HPLC‐MS method capable for enantio-
meric determination of pantoprazole in dog plasma was
reported recently. The authors used both macrocyclic
antibiotic‐based (Chirobiotic T and Chirobiotic V2) and
protein‐based (AGP and Ultron ES‐OVM) columns in
their work, but successful chiral separation was only
achieved on protein‐based columns.10
To the best of our knowledge, no report appeared so
far on the enantioseparation of pantoprazole, using
teicoplanin aglycone‐based CSP. The aim of this work
was to develop, optimize, and validate an HPLC method
for the chiral separation of pantoprazole enantiomers,
using macrocyclic‐type CSPs. In‐depth analysis of differ-
ent chromatographic parameters using face‐centered
composite design (FCCD) was used to evaluate their
influence on the enantioseparation. Another objective of
this work was to predict the enantiomer elution order
without the time‐consuming collection of pure enantio-
mers. CD spectroscopy, the dedicated technique to distin-
guish between enantiomers and the measured online
PAPP ET AL.160HPLC‐CD signal or spectral information supported by
computational method, was used for the elucidation of
enantiomer elution order. Molecular docking was applied
to simulate the interaction processes between teicoplanin
aglycone and pantoprazole enantiomers at the molecular
level, as the calculated binding energy difference between
the enantiomers could also predict the enantiomer elu-
tion order.2 | MATERIALS AND METHODS
2.1 | Materials
Macrocyclic glycopeptides‐type chiral columns with iden-
tical dimensions (100 × 4.6 mm, 5‐μm particle size)—
ristocetin A‐based Chirobiotic R, teicoplanin‐based
Chirobiotic T, teicoplanin aglycone‐based Chirobiotic
TAG, and vancomycin‐based Chirobiotic V were pur-
chased from Supelco/Astec, (Milwaukee, Wisconsin).
Pantoprazole sodium hydrate (≥98%), esomeprazole mag-
nesium hydrate (≥98%), and triethylamine (≥99%) were
ordered from Sigma‐Aldrich Hungary (Budapest). Gradi-
ent grade methanol (MeOH), acetonitrile (ACN), ethanol
(EtOH), glacial acetic acid, ammonium acetate (≥98%),
ammonium formate (≥99%), and formic acid (≥98%) were
purchased from Merck (Darmstadt, Germany). Controloc
20‐mg tablets were obtained from Central Pharmacy of
Semmelweis University (Budapest, Hungary). Ultrapure,
deionized water was prepared by a Milli‐Q Direct 8
Millipore system (Milford, Massachusetts).2.2 | LC‐UV analysis
LC‐UV analysis was carried out on a JASCO HPLC sys-
tem (JASCO PU‐2089 Plus binary gradient pump, AS‐
4050 autosampler, MD‐2010 Plus diode array detector
and column oven [CO2065 plus]). The software used for
the operation of the equipment and data processing was
ChromNAV. UV detection was performed at 288 nm.
Stock solutions of 1‐mg/mL pantoprazole were prepared
in MeOH and were further diluted with the same solvent.
An injection volume of 10 μL was used, and three parallel
measurements were performed in all cases. Other chro-
matographic conditions including validation processes
are given in Section 3.2.3 | LC‐CD method
The inline CD spectra of the separated enantiomers were
measured by an LC system composed of a JASCO intelli-
gent pump (PU‐980), hyphenated with a JASCOspectropolarimeter (J720) equipped with a flow through
cell (path length: 0.5 cm), suitable for the simultaneous
detection of CD and UV spectra (JASCO, Tokyo, Japan).
During this method, 1‐mg/mL pantoprazole solutions
were prepared in methanol, and 20 μL of these solutions
were injected on the Chirobiotic TAG column using a
Rheodyne injector. The signs of CD signal of
pantoprazole enantiomers at 273 and 229 nm were com-
pared with those of esomeprazole. The esomeprazole
(c = 0.5 mg/100 mL in methanol) CD spectrum was
recorded on the same JASCO J720 spectropolarimeter in
a 1‐cm quartz cuvette at 25°C. The spectrum was col-
lected from three times accumulation with a bandwidth
of 1 nm and a scanning step of 0.2 nm at a scan speed
of 50 nm/min. Besides, high‐speed, multiscan CD spectra
were also registered continuously between 240 and 330
nm with 1000‐nm/min scanning speed during the separa-
tion process.2.4 | Pharmaceutical sample preparation
Ten Controloc tablets were weighted and afterwards
ground and mixed in a mortar. Then an amount of pow-
der equivalent to 20 mg of racemic compound was dis-
solved in 100‐mL methanol. The suspension was
sonicated for 10 minutes and then centrifuged for 10
minutes applying 4000 rpm (Sartorius 2‐16P benchtop
centrifuge, Goettingen, Germany). The clear supernatant
was filtered through a 0.22‐μm pore size syringe filter
and diluted with MeOH to the appropriate concentrations
before injection. Determination of the pantoprazole con-
tent in pharmaceutical formulation was performed in
triplicate.2.5 | HPLC‐ESI‐QqQ‐MS methods
LC–ESI–MS/MS analysis was carried out on an Agilent
1260 Infinity HPLC system (G1312B binary gradient
pump, G1367E autosampler) hyphenated with an Agilent
6460 triple quadrupole system equipped with a JetStream
(ESI) ion source (Agilent Technologies, Waldbroon, Ger-
many). The ESI was operated in positive ion mode. High
purity N2 was used as collision gas. Applied ion source
parameters for pantoprazole were the following: flow
and temperature of the drying gas (N2): 10 L/min and
250°C, pressure of the nebulizer gas (N2): 45 psi, capillary
voltage: 3000 V, nozzle voltage: 500 V, sheath gas flow
and temperature: 10 L/min and 300°C, respectively.
Multiple reaction monitoring (MRM) transitions for
the target analytes, associated fragmentor voltages, and
collision energies were automatically determined in posi-
tive ion mode using Agilent MassHunter Optimizer
PAPP ET AL. 161Software. Two transitions were used to identify and quan-
tify pantoprazole 384.1 200.0 MRM transition with 80‐V
fragmentor voltage and 8‐eV collision energy were the
parameters of quantifier ion and 384.1 138.1 transition
with 80‐V fragmentor voltage and 36‐eV collision energy
were the parameters of qualifier ion. Mass spectra were
processed by Agilent MassHunter B.04.00 software.
HPLC‐MS/MS measurements were used to detect the
pantoprazole enantiomers in 5‐ng/mL concentration in
spiked mouse serum sample. Therefore, an appropriate
amount of pantoprazole stock solution was added to
200‐μL mouse serum sample. After 1 minute on vortex,
samples were centrifuged at 8000 rpm for 10 minutes.
The supernatant was transferred to a glass vial and evap-
orated under nitrogen gas stream to complete dryness.
The residue was dissolved in 100‐μL purified water and
filtered through 0.22‐μm syringe filter. The resulting solu-
tion was injected into the HPLC/ESI‐MS system. The
injection volume was 10 μL.2.6 | Docking simulations
The structure of teicoplanin aglycone (TAG) was
obtained from the Protein Data Bank (rcsb.org),13 by
downloading the 3mgb entry.14 The 3mgb is a molecular
complex containing TAG and other molecules. Only one
teicoplanin aglycone molecule was kept, while the other
parts of the complex (protein, water, etc) were deleted.
Hydrogens were added, then, partial charges were com-
puted, and the resulting TAG structure was minimized
by using the MMFF94x force field.15 This minimized
structure has been used as host in docking simulations.
Pantoprazole enantiomers were docked by using
AutoDock Vina,16 and their affinity towards the
teicoplanin aglycone model was determined. The grid
box in the calculations was 30 × 30 × 30 Å3, the maxi-
mum number of binding modes was set to 9, while the
exhaustiveness was 8. Binding affinities (ΔEA) of the best
pantoprazole binding modes were compared.2.7 | Quantum chemical calculations
Geometry and frequency calculations were carried out at
the M06‐2X/6‐31G(d)/CPCM (methanol) level of the-
ory.17-19 The optimized structures of the pantoprazole
enantiomers were used to compute their CD spectra at
M06‐2X/6‐311 + G(2d,p)/CPCM (methanol) level of the-
ory.17-19 Overlapping Gaussian functions with σ = 0.20
eV fitting parameter were applied to simulate the CD
spectra in the SpecDis program.20-22 All quantum chemi-
cal calculations were carried out by using the Gaussian 09
program package.233 | RESULTS AND DISCUSSION
3.1 | Preliminary screening
The enantiomeric resolution capabilities of the four mac-
rocyclic antibiotic‐type CSPs (Chirobiotic TAG,
Chirobiotic T, Chirobiotic R, and Chirobiotic V2) were
evaluated, in polar organic, polar ionic, and reversed‐
phase chromatographic mode. In polar organic mode,
pure MeOH and ACN were used. In polar ionic mode,
0.1% ammonium formate or acetic acid/triethylamine
mixture in different ratios was added to MeOH or ACN
in order to facilitate ionization of the analyte. In
reversed‐phase mode, eluents containing mixtures of
ACN/water, MeOH/water, and EtOH/water in different
proportions were used to establish the most suitable
organic modifier. In all preliminary experiments, a con-
stant 0.5‐mL/min flow rate and 20°C column temperature
was used.
Preliminary chromatographic runs revealed that under
the applied conditions, only the teicoplanin aglycone‐
based Chirobiotic TAG column has enantiorecognition
ability for pantoprazole enantiomers. The highest
enantiorecognition ability was achieved in reversed‐phase
mode when using a 60/40 (v/v%) MeOH/water mobile
phase. Further experiments were carried out to evaluate
the pH dependence of the chiral separation; 0.1 % acetic
acid (pH 3.30), 20‐mM ammonium acetate/acetic acid
(pH 5.00), and 20‐mM ammonium acetate (pH 6.90) were
used as aqueous component of the mobile phase, while
the MeOH/water ratio was kept constant 60/40 (v/v%).
No significant differences were obtained in enantiomeric
resolution or retention times using the above‐mentioned
mobile phase compositions, compared with pure water.
However, 20‐mM ammonium acetate buffers resulted
the best peak shape. Taking also into account the relative
instability of pantoprazole in acidic conditions, 20mM
ammonium acetate in water (pH 6.90) was chosen for fur-
ther method optimization. The influence of column tem-
perature (10‐40°C) and flow rate (0.3‐0.8 mL/min) were
also investigated. Applying higher temperature, the reso-
lution value decreased. Based on these findings, the range
of 5°C to 15°C was chosen for the following optimization
design, while 0.5 to 0.7 mL/min flow rate range was
selected in accordance with resolution and analysis time.3.2 | Method optimization using FCCD
To optimize the analytical conditions and to investigate
the effect of the different chromatographic parameters
on the separation a face‐centered central composite
design (FCCD) for three factors with 20 experiments
PAPP ET AL.162was applied. The variable analytical parameters and their
applied ranges were as follows: MeOH percentage in the
mobile phase (50%‐70% v/v) (factor A) column tempera-
ture (5°C‐15°C) (factor C) and flow rate (0.5‐0.7
mL/min) (factor B). As a result, two experimental
responses were screened: resolution value between
pantoprazole enantiomers and retention time of the sec-
ond eluting enantiomer.
The experimental plan and the results are summarized
in Table 1.
A second‐order polynomial quadratic model was
applied, and analysis of variance (ANOVA) was carried
out to estimate the significance of the model. The insig-
nificant model terms were deleted one by one, while the
model was re‐evaluated after each deleted term. The fol-
lowing final regression models were obtained for the res-
olution and analysis time, respectively:
Resolution ¼ þ1:90 − 0:16*A − 0:13*B
þ 0:017*C − 0:078*A2
þ 0:042*B2 − 0:19*C2 (1)TABLE 1 Experimental plan with obtained results
Experiments Factors Responses
Standard
Order
Run
Order
Factor
A
Factor
B
Factor
C Rs
tr
*
(min)
3 1 50 0.7 5 1.68 10.21
15 2 60 0.6 10 1.86 8.47
5 3 50 0.5 15 2.01 15.81
13 4 60 0.6 5 1.69 6.93
8 5 70 0.7 15 1.42 4.01
11 6 60 0.5 10 2.07 10.26
10 7 70 0.6 10 1.68 5.27
12 8 60 0.7 10 1.82 7.11
4 9 70 0.7 5 1.36 3.92
6 10 70 0.5 15 1.61 5.71
14 11 60 0.6 15 1.74 6.41
7 12 50 0.7 15 1.71 11.28
17 13 60 0.6 10 1.90 8.60
18 14 60 0.6 10 1.86 8.24
20 15 60 0.6 10 1.91 8.26
19 16 60 0.6 10 1.93 8.27
2 17 70 0.5 5 1.64 5.77
9 18 50 0.6 10 1.97 9.25
1 19 50 0.5 5 1.95 15.59
16 20 60 0.6 10 1.90 8.25
Note. Factor A—methanol content (%, v/v); Factor B—flow rate (mL/min);
Factor C—temperature (°C); *tr—retention time of the second eluting
enantiomer.Analysis time ¼ þ7:80 − 3:75*A − 1:66*B
þ 0:79*A*Bþ 1:17*B2 (2)
where A is the methanol content in % (v/v), B is the
flow rate in milliliters per minute, and C is the tempera-
ture in degree celcius.
By increasing the methanol content of the mobile
phase, a shortened analysis time was observed, while
the resolution optimum was around 60%. Upon enhanc-
ing the flow rate, both resolution and analysis time
decreased. The temperature influenced the resolution to
a great extent, which reached a maximum value around
10°C, while it had no significant effect on the analysis
time in the studied range (5‐15°C).
Both models showed good performance indicators: R2
= 0.9866, R2adj = 0.9804 for resolution and R
2= 0.9292,
R2adj = 0.9104 for analysis time, respectively. The values
obtained verify that both estimated models fit the experi-
mental results.
Three‐dimensional response surface plots obtained by
the regression models are presented in Figure S1.
In order to establish an optimal combination of the
studied analytical conditions for both responses, the Der-
ringer desirability function was applied. In this approach,
experimental results are transformed in desirability
values on a scale between 0 and 1, 0 representing the
most undesirable and 1 the most desired outcome of each
response of interest. In our case, resolution had to be
enhanced, and analysis time had to be minimized. Global
desirability was calculated as geometric mean of the indi-
vidual desirability values, and then the overall optimum
was searched in the experimental space.
Optimal analytical conditions obtained, based on the
desirability function, were as follows: Chirobiotic TAG
stationary phase, thermostated at 10°C, mobile phase
consisting of methanol/20mM ammonium acetate 60:40
v/v, and 0.6‐smL/min flow rate.
Using these optimal analytical conditions, baseline res-
olution (Rs = 1.91 ± 0.03) within 10 minutes was
achieved between pantoprazole enantiomers.3.3 | Method validation and application
To prove that our method is appropriate and reliable, a
validation study was carried out according to ICH guide-
lines, based on precision, linearity, accuracy, limit of
detection (LOD), and limit of quantification (LOQ).
Method precision was evaluated based on intraday and
interday precisions. Six consecutive injections (n = 6)
from a standard solution (c = 20 μg mL−1) were per-
formed in order to estimate the intraday precision by cal-
culating the RSD values for peak areas for each
PAPP ET AL. 163enantiomer. Interday precision was determined by
performing six injections of a standard solution (c = 20
μg mL−1) over three consecutive days (n = 18), and calcu-
lating RSD values for peak areas. Linearity of the models
was investigated over the concentration range 1 to 50 μg
mL−1, at six concentrations, using three replicates at each
concentration level. LOD and LOQ were calculated from
signal/noise ratio 3:1 and 10:1, respectively. Method accu-
racy was investigated by recovery experiments at three
concentration levels for both enantiomers, covering the
linearity range, each solution injected in triplicate. The
validation data including precision, accuracy, and linear-
ity, LOD, and LOQ values are summarized in Table 2.
The validated method was applied for the chiral sepa-
ration and quantitative determination of pantoprazole
from a commercially available dosage form. Results of
the quantitative evaluation are presented in Table 3.
Recoveries were in good agreement with the declared
drug content. Moreover, no interference was observed
on the chromatograms from drug formulation excipients
(Figure 2A). Using our optimized HPLC method supple-
mented with optimized MS/MS parameters, pantoprazole
enantiomers in 5‐ng/mL concentration were detected inTABLE 2 Method validation data
Pantoprazole
S‐
pantoprazole
R‐
pantoprazole
Precision
Intraday
(conc = 20 μg
mL−1, n = 6)
RSD% of
peak area
1.17 1.32
Interday
(conc. = 20 μg
mL−1, n = 18)
RSD% of
peak area
1.59 1.82
Accuracy (Recovery %)
5 μg mL−1 (n = 3) 101.22 102.4
10 μg mL−1 (n = 3) 100.33 99.94
30 μg mL−1 (n = 3) 99.11 98.36
Linearity
Regression equation
(1‐50 μg mL−1)
y = 0.245x +
1.065
y = 0.240x +
0.896
R2 0.999 0.998
LOD (μg mL−1/) 0.65 0.59
LOQ (μg mL−1/) 1.96 1.78
TABLE 3 Results obtained during quantification of pantoprazole ena
Pharmaceutical
product
Declared Enantiomer Quantity (mg)
1st enantiomer 2nd enantiom
Controloc 20 mg 10 10spiked mouse serum, indicating that the developed
method could be a good starting point for bioanalytical
purpose as well (Figure 2B).3.4 | Determination of enantiomer elution
order by online HPLC‐CD
Since pantoprazole enantiomer standard was not avail-
able, two approaches were applied for the elucidation of
elution order.
I. The online registered CD spectra of pantoprazole
enantiomers were compared with CD spectrum of
enantiopure esomeprazole, a chemically related
compound.ntiomers from commercially available pharmaceutical product
Found Enantiomer Quantity (mg) (n = 3)
er 1st enantiomer 2nd enantiomer
10.04 ± 0.17 10.10 ± 0.11
FIGURE 2 Representative chromatogram for the chiral
separation of pantoprazole enantiomers under optimized
analytical conditions (Chirobiotic TAG stationary phase,
thermostated at 10°C, mobile phase: methanol/20mM ammonium
acetate 60:40 v/v, 0.6 mL/min flow rate) (A) from commercially
available dosage forms (UV detection at 288 nm), (B) from spiked
mouse serum (MS detection: 384.1 200.0 MRM transition with 80 V
fragmentor voltage and 8 eV collision energy)
PAPP ET AL.164II. The inline CD signal of pantoprazole enantiomers
was compared with the quantum chemically calcu-
lated CD spectra.
HPLC coupled with a CD spectrometer can be used as
chiroptical detector, and it can be useful for determina-
tion of enantiomer elution order of racemic drugs; if
structurally similar, pure enantiomer is available. Com-
paring the character of CD spectra of the reference and
the investigated molecule, the configuration can be
assumed.24 This so‐called empirical approach implies that
a minor structural difference does not alter the CD spec-
trum of the investigated molecule.24-26 In our study, the
detected CD sign of pantoprazole enantiomers was com-
pared with the structurally related esomeprazole at two
wavelengths (229 and 273 nm), where the signs of the
CD spectrum of esomeprazole are opposite. As it can be
seen in Figure 3, both esomeprazole and the foremost
eluting pantoprazole enantiomer show positive CD signal
at 229 nm as well as similarly negative CD signal at 273
nm; thus, elution order can be empirically established
as S‐pantoprazole, followed by R‐pantoprazole.
Rapid multiscan chiroptical spectral recording method
is unique and useful method to characterize peak purity27
and determine enantiomer elution order.28
Using 1000‐nm/min scanning speed, we were able to
register two appropriate ECD spectra between 330 and
240 nm. The two spectra collected from the pantoprazole
chromatogram show mirror images of each other. The
first eluted isomer shows negative band, whereas theFIGURE 3 Comparison of circular dichroism (CD) spectrum of es
pantoprazole enantiomers at 229 (red) and 273 (black) nm. Chromatog
temperature (ambient)second eluted isomer shows positive band (Figure 4A).
To further verify the identity of the isomers, their spectra
were calculated by using M06‐2X/6‐311 + G(2d,p)/CPCM
(methanol) level of theory and compared with the exper-
imental results (Figure 4B). The calculated and measured
spectra can be paired easily and allow assigning the S‐
pantoprazole absolute configuration to the first eluted
peak, so this approach also confirmed the elution order
as being: R isomer follows S.3.5 | Docking study of pantoprazole and
teicoplanin aglycone complexes
Using molecular docking, the interactions between
pantoprazole enantiomers and teicoplanin aglycone can
be investigated at the molecular level. Furthermore, by
using molecular docking, the strength of complexation
can be compared and studied. The TAG model from a
molecular complex (PDB ID: 3MGB) was prepared and
used as host in docking simulations. AutoDock Vina
was used to dock the enantiomers and study the interac-
tions and the corresponding affinities between them and
the TAG model. The best R‐ and S‐pantoprazole binding
modes have been selected based on their binding affini-
ties towards the TAG model. The three‐dimensional (3‐
D) structures of the selected diastereomeric complexes
between pantoprazole enantiomers and TAG are pre-
sented in Figure 5 (for additional views, see Figures S2
and S3), together with the calculated relative bindingomeprazole (A) with CD (B) and UV (C) signals of the separated
raphic conditions are the same as in Figure 2, except for column
FIGURE 5 3‐D structures of the
diastereomeric complexes between
pantoprazole enantiomers and teicoplanin
aglycone (TAG) and difference between
their calculated relative binding affinities
(ΔR‐SEA)
FIGURE 4 Online registered (A) and calculated (B) circular dichroism (CD) spectra of pantoprazole enantiomers
PAPP ET AL. 165affinities. Within the formed complexes, three different
interaction types can be identified: π‐stacking, –CH–Ph
and –NH–O. The number of interactions is four (two π‐
stacking, one –CH–Ph, and one –NH–O) and five (three
π‐stacking, one –CH–Ph, and one –NH–O) in case of
the S‐ and R‐pantoprazole‐TAG complex, respectively.
More interactions can be associated with stronger bind-
ing, which is confirmed by the complexation energies of
pantoprazole enantiomers. Thus, the R‐enantiomer binds
stronger to the chiral selector than its antipode (ΔR‐SEA =
−0.3 kcal/mol), in accordance with the elution order on
the column. Our results also show that molecular
docking can efficiently contribute to predict elution order
of enantiomers.4 | CONCLUSION
Pantoprazole enantiomers were separated with a novel,
reversed‐phased HPLC method on a Chirobiotic TAG col-
umn. Our method was optimized using a multivariate
approach, leading to baseline separation of enantiomers
within 10 minutes, which is one of the fastest methods
in the literature. Further benefits of our method are that
it is environmentally friendly cheap especially compared
with the often used normal‐phased system in chiralHPLC, and it is MS‐compatible. Applicability of the
method was checked by analyzing commercial pharma-
ceutical preparations, and after MS‐hyphenation, it was
also proved that it could be a good starting point for
bioanalytical purposes as well. The study further under-
lines the ease of use of reversed‐phase mode using macro-
cyclic glycopeptide‐based CSPs. Since individual
enantiomers were not available, the method was used as
a prerequisite for the identification of the separated anti-
podes without the time‐consuming sample collection and
prediction of the elution order. Thus, methods were elab-
orated to determine the absolute configuration of the
eluted pantoprazole enantiomer peaks. Three separate
approaches were used for the determination of elution
order without isolation. At first enantiomer, elution order
was determined using HPLC coupled CD spectroscopy as
detection method, by two approaches: The online regis-
tered CD spectra of pantoprazole enantiomers were com-
pared with CD spectrum of enantiopure esomeprazole,
and the inline CD signal of pantoprazole enantiomers
was compared with the calculated CD spectra. Further-
more, molecular docking was also applied to determine
the binding strength between the chiral selector and the
enantiomers. The docking calculations showed that the
R‐pantoprazole binds stronger the chiral selector than
its antipode, in accordance with the elution order on
PAPP ET AL.166the column. Our results demonstrate the efficiency of
combined methods, HPLC‐CD and theoretical calcula-
tions, to determine enantiomer elution order.ACKNOWLEDGEMENTS
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